<DOC>
	<DOCNO>NCT00004900</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness chemotherapy plus peripheral stem cell transplantation treat woman metastatic breast cancer .</brief_summary>
	<brief_title>Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess toxicity response rate sequential high dose chemotherapy without induction chemotherapy woman metastatic breast cancer . II . Determine hematopoietic recovery rate patient infusion blood derive CD34+ progenitor isolate use CD34+ affinity device positive purification autograft . III . Compare response rate duration responses patient treated trial patient treat previous trial use sequential high dose chemotherapy induction conventional dose chemotherapy . OUTLINE : Patients receive cyclophosphamide IV daily 2 day , etoposide IV cisplatin IV daily 3 day . Filgrastim ( G-CSF ) administer subcutaneously twice daily begin 24 hour completion chemotherapy last day apheresis . Upon hematopoietic recovery , peripheral blood stem cell ( PBSC ) collect several day . Within 35 day mobilization chemotherapy , patient receive cyclophosphamide IV , thiotepa IV , carboplatin IV continuously day -7 -4 , follow 2 day rest period . CD34+ select PBSC reinfused . Beginning 4 hour reinfusion , patient receive G-CSF subcutaneously daily hematopoietic recovery . Patients may receive radiation therapy sit prior bulk disease discretion investigator . Within 30 day hematopoietic recovery immediately follow post transplant radiation therapy , patient receive oral anastrazole daily disease progression . Patients follow monthly 6 month , every 3 month 1 year , every 4-6 month 5 year , annually thereafter . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm epithelial carcinoma breast metastatic organ except brain , include ipsilateral supraclavicular ( axillary ) lymph node chest wall No apocrine , adenocystic , squamous cell carcinoma , sarcoma , lymphoma Measurable evaluable disease No stage IV disease render nonassessable surgery No symptomatic CNS disease Hormone receptor status : Must biological and/or immunocytochemical receptor assay estrogen progesterone report PATIENT CHARACTERISTICS : Age : 18 65 Sex : Female Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 3.0 mg/dL SGOT great 6 time upper limit normal Renal : Not specify Cardiovascular : Ejection fraction least 40 % MUGA No angina pectoris require active nitrate therapy No myocardial infarction within past 6 month No uncontrolled congestive heart failure , uncontrolled hypertension , major ventricular arrhythmia Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection medical condition would preclude administration high dose therapy No prior malignancy within past 5 year except inactive nonmelanoma skin cancer carcinoma situ cervix No uncompensated endocrine dysfunction HIV negative Hepatitis B negative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No 1 prior course adjuvant therapy No prior chemotherapy metastatic breast cancer At least 6 month since prior adjuvant therapy No cumulative doxorubicin equivalent dose great 360 mg/m2 adjuvant set Endocrine therapy : Prior hormonal therapy metastatic disease allow Radiotherapy : Not specify Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>